戻る Agenda
Session 8B: Update on ICH M9 Gaps
Session Chair(s)
Roger Nosal, PhD
Vice President, Head of Global CMC
Pfizer Inc, United States
The development of biosimilars is increasing at a fast pace. This session will first look at the approvals granted so far in the US and EU for biosimilars as well as the current regulatory frameworks in these regions (eg guidance on interchangebility). Case studies will then address the obstacles for biosimilars in the CMC area and how these can be circumveted. In the end, CMC regulatory considerations for global development/ global regulatory submission will be discussed.
Speaker(s)
Definition of Solubility (Maximum Therapeutic Dose vs. Highest Strength) and Requirement of Dose-Proportionality (Dose Exposure)
Jack Cook
Pfizer Inc., United States
Vice President, Clinical Pharmacology
Definition of Permeability (Relative Value of In Vitro Data)
Mehul Mehta, PhD
FDA, United States
Director, Division of Clinical Pharmacology, OCP, OTS, CDER
Dissolution and Formulation Criteria (Justification for Dissolution Criteria/Media; Excipient Impact on BA)
Patrick J Marroum, PhD
AbbVie, United States
Senior Research Fellow